Under the corporate philosophy
of 'Otsuka - people creating new products
for better health worldwide,' Otsuka Pharmaceutical
Co., Ltd. is engaged in the production and
sale of innovative, creative pharmaceuticals,
nutritional products, and cosmetics, aiming
to be a global value-creating company that
contributes to the health and wellness of
people worldwide.
|
|
| Pletaal |
 |
Indications:
Treatment of ischemic symptoms, including ulceration,
pain, and coldness of the extremities, in chronic
arterial occlusion.
Prevention of recurrence of cerebral infarction
(excluding cardiogenic cerebal embolism).
Contraindications:
Patients with hemorrhage (e.g. hemophilia,
increased capillary fragility, intracranial
hemorrhage, hemorrhage in the digestive tract,
hemorrhage in the urinary tract, hemoptysis,
and hemorrhage in the vitreous body) (Bleeding
tendency may be increased.) Patients with
congestive heart failure (Condition may be
worsened.) Patients with history of hypersensitivity
to any of ingrediens of the drug. Women who
are pregnant or may possibly become pregnant.
|
Dosage
and Administration:
The usual adult dose of Pletaal® tablets
is 100 mg of cilostazol, twice daily, by the
oral route. The dosage may be adjusted according
to the age of the patient and the severity of
symptoms.
Packaging / Availability:
• Pletaal® 50-mg Tablets:
Box of 100 tablets in foil sheet of 10's
• Pletaal® 100-mg Tablets: Box of
100 tablets in foil sheet of 10's
|
|
| The event rate per year for
the composite outcome of stroke, myocardial
infarction or vascular death in the Cilostazol
group was only 4.16% against placebo. Other
antiplatelets had relatively higher event rates.
Cilostazol (Pletaal) has lower even rate
of stroke, MI, or vascular death as compared
to other antiplatelets.
|
|
| Cilostazol (Pletaal®)
is safe and effective in preventing the recurrence
of cerebral infarction. An analysis based
on 1,052 eligible patients (526 given Cilostazol
100 mg b.d. and 526 given placebo over 1200
days) showed that Cilostazol treatment achieved
a significant relative-risk reduction of 41.7%
confidence interval (CI), 9.2% to 62.5%) in
the recurrence of cerebral infarction as compared
with placebo treatment (p=0.0150).
|
|
.gif){kind=small}